Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Barazzuol, Lara ^a   Jena, Raj ^b,c   Burnet, Neil G ^b,c   Meira, Lisiane B ^a   Jeynes, Jonathan C G ^a   Kirkby, Karen J ^a   Kirkby, Norman F ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ABT 888; Glioblastoma; PARP inhibition; Radiation; Temozolomide

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TEMOZOLOMIDE; VELIPARIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL NUCLEUS; CELL SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; X IRRADIATION;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; DACARBAZINE; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84875018599     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-65     Document Type: Article

References (35)

1. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden and should be considered when allocating research funds. Br J Cancer 2005, 92:241-245. 2361853, 15655548.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
4. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
5. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007, 13:2728-2737. 10.1158/1078-0432.CCR-06-3039, 17473206.
6. Barazzuol L, Jena R, Burnet NG, Jeynes JC, Merchant MJ, Kirkby KJ, Kirkby NF. In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma. Radiat Res 2012, 177:651-662. 10.1667/RR2803.1, 22468703.
7. Kirkby KJ, Grime GW, Webb RP, Kirkby NF, Folkard M, Prise K, Vojnovic B. A scanning focussed vertical ion nanobeam: A new UK facility for cell irradiation and analysis. Nucl Instrum Meth B 2007, 260:97-100.
8. Clinical trial registry http://clinicaltrials.gov/.
9. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 2009, 8:407-414. 10.1158/1535-7163.MCT-08-0854, 2692390, 19174557.
10. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13:3033-3042. 10.1158/1078-0432.CCR-06-2872, 17505006.
11. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009, 8:2232-2242. 10.1158/1535-7163.MCT-09-0142, 19671751.
12. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. J Clin Oncol 2009, 27:2705-2111. 10.1200/JCO.2008.19.7681, 2739635, 19364967.
13. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res 2011, 71:5626-5634. 10.1158/0008-5472.CAN-11-1227, 3166628, 21795476.
14. Valenzuela MT, Guerrero R, Núñez MI, Ruiz De Almodóvar JM, Sarker M, de Murcia G, Oliver FJ. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002, 21:1108-1116. 10.1038/sj.onc.1205169, 11850828.
15. Wieler S, Gagné JP, Vaziri H, Poirier GG, Benchimol S. Poly(ADPribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J Biol Chem 2003, 278:18914-18921. 10.1074/jbc.M211641200, 12642583.
16. The Cancer Genome Atlas (TCGA) Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. 10.1038/nature07385, 2671642, 18772890, The Cancer Genome Atlas (TCGA) Research Network.
17. Chalmers AJ. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med Chem 2010, 10:520-533. 10.2174/187152010793498627, 20879987.
18. Noël G, Godon C, Fernet M, Giocanti N, Mégnin-Chanet F, Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 2006, 5:564-574. 10.1158/1535-7163.MCT-05-0418, 16546970.
19. Dungey FA, Lö ser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly (ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008, 72:1188-1197. 10.1016/j.ijrobp.2008.07.031, 18954712.
20. Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE, Chakraborty C, Barreto-Andrade JC, Crawley C, Sutton HG, Kron SJ, Weichselbaum RR. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence inirradiated breast cancer cells and tumors. Cancer Res 2010, 70:6277-6282. 10.1158/0008-5472.CAN-09-4224, 2912962, 20610628.
21. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008, 88:258-268. 10.1016/j.radonc.2008.04.005, 18456354.
22. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006, 16:2-9. 10.1016/j.semradonc.2005.08.001, 16378901.
23. Hei TK, Piao CQ, Geard CR, Hall EJ. Taxol and ionizing radiation: interaction and mechanisms. Int J Radiat Oncol Biol Phys 1994, 29:267-271. 10.1016/0360-3016(94)90273-9, 7910816.
24. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, Zhu GD, Penning TD, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009, 15:7277-7290. 10.1158/1078-0432.CCR-09-1245, 19934293.
25. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779-784. 10.1016/S0360-3016(99)00539-8, 10837964.
26. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006, 12:4738-4746. 10.1158/1078-0432.CCR-06-0596, 16899625.
27. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007, 69:1246-1253. 10.1016/j.ijrobp.2007.07.2366, 17967314.
28. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008, 14:931-938. 10.1158/1078-0432.CCR-07-1856, 18245557.
29. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anti-cancer drugs 1997, 8:92-97. 10.1097/00001813-199701000-00013, 9147618.
30. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006, 96:766-776. 10.1111/j.1471-4159.2005.03583.x, 16405512.
31. Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007, 68:873-882. 10.1016/j.ijrobp.2007.03.002, 17544000.
32. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys 2009, 75:1511-9. 10.1016/j.ijrobp.2009.07.1703, 19931733.
33. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to doublestranded DNA breaks. Mol Cancer Res 2008, 6:1621-1629.
34. Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower MC, Yang ES. Cetuximab augments cytotoxicity with poly (ADPribose) polymerase inhibition in head and neck cancer. PLoS One 2011, 6:1-11.
35. Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 2011, 71:4944-4954. 10.1158/0008-5472.CAN-11-0814, 3138894, 21613406.